BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 10897048)

  • 21. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
    Weber W; Weber J; Senekowitsch-Schmidtke R
    Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma.
    Accorsi R; Morowitz MJ; Charron M; Maris JM
    Pediatr Radiol; 2003 Oct; 33(10):688-92. PubMed ID: 12908090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
    Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
    Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
    Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
    Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.
    Vaidyanathan G; Affleck DJ; Alston KL; Welsh P; Zalutsky MR
    Nucl Med Commun; 2004 Sep; 25(9):947-55. PubMed ID: 15319601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
    Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
    Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
    J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
    McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
    J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
    Gaze MN; Mairs RJ; Boyack SM; Wheldon TE; Barrett A
    Br J Cancer; 1992 Dec; 66(6):1048-52. PubMed ID: 1457344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG].
    Sudbrock F; Eschner W; Schmidt M; Simon T; Hero B; Schicha H
    Nuklearmedizin; 2006; 45(6):254-61. PubMed ID: 17149494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.
    Zhang H; Huang R; Cheung NK; Guo H; Zanzonico PB; Thaler HT; Lewis JS; Blasberg RG
    Clin Cancer Res; 2014 Apr; 20(8):2182-91. PubMed ID: 24573553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines.
    Meco D; Lasorella A; Riccardi A; Servidei T; Mastrangelo R; Riccardi R
    Eur J Cancer; 1999 Aug; 35(8):1227-34. PubMed ID: 10615234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for
    Seo Y; Huh Y; Huang SY; Hernandez-Pampaloni JM; Hawkins RA; Gustafson WC; Vo KT; Matthay KK
    Med Phys; 2019 May; 46(5):2477-2486. PubMed ID: 30761545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SIMS microscopy imaging of the intratumor biodistribution of metaiodobenzylguanidine in the human SK-N-SH neuroblastoma cell line xenografted into nude mice.
    Clerc J; Halpern S; Fourré C; Omri F; Briançon C; Jeusset J; Fragu P
    J Nucl Med; 1993 Sep; 34(9):1565-70. PubMed ID: 8355077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
    Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic use of I-131-MIBG in nude mice hosting human neuroblastoma xenografts.
    Senekowitsch R; Laubenbacher C; Möllenstädt S; Kriegel H; Pabst HW
    Strahlenther Onkol; 1989 Jul; 165(7):566-8. PubMed ID: 2749502
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
    Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
    Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.
    Gaze MN; Gains JE; Walker C; Bomanji JB
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):66-78. PubMed ID: 23474636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.
    Lashford LS; Moyes J; Ott R; Fielding S; Babich J; Mellors S; Gordon I; Evans K; Kemshead JT
    Eur J Nucl Med; 1988; 13(11):574-7. PubMed ID: 3350034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.